

# THE HOBART LIPID SYMPOSIUM




**Saturday 17<sup>th</sup> September 2005**

Time	Speaker	Topic
8.30am	<b>Registration Desk Opens in the Foyer of the Old Woolstore, Macquarie St , Hobart, with Morning Tea etc. available</b>	
9:00am	Dr Udayan Ray	Welcome and Opening Remarks
	Session One Chair : Dr Udayan Ray	
9:10am	Prof David Thomas	Fractionating the Hyperlipidaemias and their Role in Determining Clinical Prognosis
10:10am	Dr Tom Hartley	Are My Lipids Falling ?
10:40am	Tess Camfield	New Pharmacological Agents for the Management of Hypercholesterolaemia and Hyperlipidaemia.
11:10am	Prof David Sullivan	The Role of Molecular Medicine in the Explanation of Cholesterol and Lipid Disorders.
11:40		<b>11:40 – 12:30 LUNCH</b>
	Session Two Chair : Dr Tom Hartley	
12:30pm	Prof David Kilpatrick	Hyperlipidaemia : Who Should Not Be Treated With Lipid Lowering Drugs ?
1:00pm	Dr Kelly Shaw	<b>Obesity - Public Health Perspectives</b>
1:30pm	Prof Phil Roberts-Thompson	Atherosclerosis and the Normal Ageing Process
2:00pm	Prof David Sullivan	Gene - Environment Interactions Affecting Obesity, Diabetes and Cardiovascular Disease.
3:00pm	Chair : Dr Udayan Ray	PANEL DISCUSSION and Closing Remarks
3:30pm		<b>3:30 – 4:00 Networking during Afternoon Tea</b>

## SPONSORS

Royal Hobart Hospital  
 Merck Sharp & Dohme Servier Laboratories  
 Australian Association of Clinical Biochemists Centrepath Pathology



# THE HOBART LIPID SYMPOSIUM



## SPEAKER PROFILES

**Prof David Thomas:** David graduated in Medicine from the University of Adelaide in 1966. He completed physician training at the Royal Adelaide Hospital and then joined the Institute of Medical and Veterinary Science (IMVS) and completed training in Chemical Pathology there, and later at the Institute of Health, Bethesda, USA. He was appointed Head of the Division of Clinical Chemistry at the IMVS in 1980. In 1993 he was appointed to the Chair of Chemical Pathology in the Department of Paediatrics at the University of Adelaide with the concomitant responsibilities as Head of Chemical Pathology Services at the Women's and Children's Hospital. In November 2001, he joined Gribbles Pathology as Medical Director in South Australia. Subsequent appointment as Adjunct Professor in the Department of Paediatrics at the University of Adelaide has enabled him to continue his teaching activities. Throughout his career he has continued clinical practice in the area of lipid and other metabolic disorders.


**Prof David Sullivan:** MBBS, FRACP, FRCPA, Clinical Associate Professor at the Department of Biochemistry, Royal Prince Alfred Hospital, Sydney, NSW. David has a long-term interest in lipid metabolism with particular emphasis on the environmental component (particularly dietary) of gene – environment interactions contributing to cardiovascular disease. He has been involved in the early use of many forms of lipid-lowering intervention and has a particular interest in interventions arising from nutritional principles, such as the cholesterol-lowering effect of plant sterols. His other main interest is the improvement of detection and management of severe inherited dyslipidaemia, such as that seen in Familial Hypercholesterolaemia. David has experience in several international clinical posts, including time spent at the MRC Lipoprotein Unit, Royal Postgraduate School of Medicine, Hammersmith Hospital, London and co-ordination of international clinical studies from the WHO reference lipid laboratory in Wageningen, Netherlands.

**Prof David Kilpatrick:** David studied Physics and then Medicine in New Zealand before going to London as a Commonwealth Scholar to study Cardiology. While at Hammersmith Hospital he worked with Gil Thomson for three years on plasma exchange in familial hypercholesterolaemia following that he worked on the biophysics of the electrocardiogram and the physics of coronary flow. David came to Tasmania in 1981 from San Francisco to positions as Senior Lecturer UTas Clinical School and Cardiologist at the Royal Hobart Hospital. David was promoted to Professor in 1993. His current interests are in pulmonary hypertension as well as cardiac biophysics.

**Prof Phil Roberts-Thompson:** Director of Cardiology, Royal Hobart Hospital. Phil is a Tasmanian Medical Graduate who trained in Cardiology at Flinders Medical Centre and at the Royal Adelaide Hospital. He was awarded his PhD by Flinders University. He worked for two years at the University of Iowa before returning to Hobart in 1999 where he has been Director of Cardiology since 2003.

**Tess Camfield:** Specialist Pharmacist, Critical Care, Royal Hobart Hospital. Tess qualified as a Pharmacist in 1999 in the UK and continued to practice within the hospital setting at St George's Hospital, London. Prior to moving to the Royal Hobart Hospital she worked at the Auckland Hospital. She has been in her current position for the past 18 months.

**Dr Kelly Shaw:** Public Health Registrar, Public and Environmental Health Service, DHHS. Kelly qualified as a General Practitioner before commencing public health training. Her MPH focussed on behavioural medicine and her PhD is related to the public health aspects of obesity management. She has recently been appointed to the scientific reference group of the National Obesity Taskforce and has produced meta-analyses for the Cochrane Collaboration Metabolic and Endocrine Disorders Review Group in the area of evidence-based management of obesity.




# THE HOBART LIPID SYMPOSIUM




**Dr Udayan Ray:** Chemical Pathologist, Pathology Department, Royal Hobart Hospital. Udayan has worked in India, Papua New Guinea and New Zealand. Since arriving in Hobart in 2003 he has been an enthusiastic educator of both undergraduate Medical Students and postgraduate Scientific Staff. He has a longstanding research interest in nitric oxide and its role in cardiac metabolism and cardiac disease.

**Dr Tom Hartley:** Quality Manager and a Senior Biochemist, Pathology Department, Royal Hobart Hospital. He is also a Senior Research Fellow at the School of Human Life Sciences, University of Tasmania. He obtained his PhD from the University of Leeds, did his post doc research in Portsmouth UK, before moving to the IMVS, Adelaide in 1974. He moved to Hobart in 1988. He has longstanding interests in instrumental methods of biochemical analysis and in clinical laboratory statistics.

## LIPOPROTEINS IN HUMAN PLASMA



	<b>Chylomicrons</b>	<b>VLDLs</b>	<b>IDLs</b>	<b>LDLs</b>	<b>HDLs</b>
Molecular weight x 10 <sup>-6</sup>	>400	10-80	5-10	2.3	0.18-0.36
Density (g cm <sup>-3</sup> )	<0.95	0.95-1.006	1.006-1.019	1.019-1.063	1.063-1.210
<b>Chemical composition (%)</b>					
Protein	2	10	18	25	33
Triacylglycerol	85	50	31	10	8
Cholesterol	4	22	29	45	30
Phospholipid	9	18	22	20	29



# THE HOBART LIPID SYMPOSIUM



## SPONSORS

**EMMA RYAN** R.N.

Senior Medical Representative  
Tasmania  
Metabolic Division

Mobile 0411 429 340

emma.ryan@au.netgrs.com



Servier Laboratories (Australia) Pty Ltd  
ABN 54 004 838 500

8 Cato Street Hawthorn  
Victoria Australia 3122  
PO Box 196 Hawthorn 3122

Telephone (03) 8823 7333  
Facsimile (03) 9822 9790  
Customer Service 1800 33 1675

**Jim Duggan** B. Sc. (Biology)  
Executive Professional Representative  
Tasmanian Resident



**MERCK SHARP & DOHME**  
EZETROL Primary Care Team

Merck Sharp & Dohme (Australia) Pty Limited  
PO Box 245, Moonah TAS 7009  
Tel 03 8698 1600 Mobile 0419 321 787  
Fax 03 9646 9435 Email jim\_duggan@merck.com



Royal Hobart Hospital  
Education and Training  
Grants

